2018 American Transplant Congress
Novel Low Dosing of Rabbit Antithymocyte Globulin Preserves Excellent Outcomes and Improves the Value of Care in Low Risk Renal Transplantation
University of Virginia Health System, Charlottesville, VA.
Elderly and non-sensitized renal transplant patients may benefit from lesser induction immunosuppression. This study evaluates three year clinical outcomes of a low risk renal transplant…2018 American Transplant Congress
mTOR Inhibition with Everolimus in De Novo Living Donor Liver Transplantation – 24-Months Results from the H2307 Pivotal Trial
Purpose: Everolimus (EVR) with reduced-dose tacrolimus (rTAC) has been shown to be efficacious in preventing graft rejection and improving renal function in deceased-donor liver transplant…2018 American Transplant Congress
The Impact of Conversion from Immediate Release Twice-Daily Tacrolimus (Prograf®) to Once-Daily Extended Release Tacrolimus (Envarsus®) in Liver Transplant Recipients
The safety and efficacy of substitution with a novel once-daily extended-release tacrolimus (LCPT;Envarsus®)to immediate-release tacrolimus (IR-Tac, Prograf®) twice daily in liver transplant patients have not…2018 American Transplant Congress
Clinical Outcomes of Conversion from Calcineurin Inhibitor to Belatacept-Based Immunosuppression in Highly Sensitized Kidney Transplant Recipients
Cedars Sinai Medical Center, Los Angeles.
Introduction:Efficacy of belatacept when converted from calcineurin inhibitors (CNI) in high immunologic risk patients has not been established. We examined the impact of HLA-sensitization on…2018 American Transplant Congress
A Six-Month, Prospective, Single-Center, Pilot Study to Determine the Pharmacokinetics and Effectiveness of Immunosuppressant Regimens in Liver Transplantation Patients Receiving Twice-Daily Tacrolimus and Everolimus (TAC + EVR BID) Regimen Converted to Once-Daily Tacrolimus and Everolimus (TAC + EVR QD) Regimen – A Priliminary Report
Adherence to immunosuppressant regimen is crucial for graft survival and usually inversely related to the dose frequency. Similar efficacy and safety profile has been approved…2018 American Transplant Congress
CTLA4-Ig and Bortezomib Successfully Reverses Established DSA Responses in Allograft-Sensitized Recipients
Background: Sensitized recipients have lower rates of transplantation and poorer outcomes. We and others have reported that the delayed administration of CTLA4-Ig can disrupt fully-established…2018 American Transplant Congress
Primary Oral Vancomycin Prophylaxis Reduces the Incidence of Clostridium difficile Infection among Lung Transplant Recipients
Cleveland Clinic Foundation, Cleveland, OH.
Purpose: To determine the efficacy of primary oral vancomycin prophylaxis in reducing the incidence of Clostridium difficile infection (CDI) in the early post-op period among…2018 American Transplant Congress
Donor Derived Transmissions in 2016-2017: Analysis of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC)
DTAC, United Network for Organ Sharing, Richmond, VA.
The DTAC evaluates unanticipated potential donor-derived transmission events (PDDTE), including mostly infections (I) & malignancies (M), to assess for likelihood of donor transmission. Reporting policy…2018 American Transplant Congress
Closing Pandora's Box: An Evidence Based Approach to Opioid-Tolerant Patients Following Transplantation. The Case for IV Methadone
Department of Surgery, Beaumont Health, Royal Oak, MI.
The purpose of this study is to explore the use of parenteral methadone in opioid-tolerant patients who are status-post transplantation. As an alternative to traditional…2018 American Transplant Congress
Everolimus with Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplant Recipients: Efficacy and Safety Outcomes from the TRANSFORM Study
1TRANSFORM Study Group, Livingston; 2Novartis Pharma AG, Basel, Switzerland.
Purpose: Everolimus (EVR)-facilitated calcineurin inhibitor (CNI) reduction regimens help prevent long-term CNI nephrotoxicity in kidney transplant recipients (KTxRs). TRANSFORM (NCT01950819) is the largest study in…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 14
- Next Page »